Navigation Links
Alzheimer's prevention trial to monitor reactions to higher disease risk status
Date:3/19/2014

PHILADELPHIA - A new clinical trial will soon begin testing whether early medical intervention in people at risk for Alzheimer's can slow down progression of disease pathology before symptoms emerge, as outlined in Science Translational Medicine. For the first time, people with no Alzheimer's disease symptoms will be told of their risk status before being asked to join the randomized controlled trial. As part of the overall prevention trial, Penn Medicine neurodegenerative ethics experts will monitor how learning about their risk of developing Alzheimer's impacts trial participants.

Alzheimer's disease afflicts more than 13 percent of individuals over the age of 65, and remains one of the most feared consequences of aging.

"In order to ethically conduct a study where patients will learn they have a greater chance of developing Alzheimer's disease dementia, we've integrated continual assessments of potential participants throughout the process, to ensure that they are ready to receive information about their amyloid status and aren't having any adverse reactions after finding out," said Jason Karlawish, MD, professor of Medicine and Medical Ethics and Health Policy in the Perelman School of Medicine at the University of Pennsylvania and Associate Director of the Penn Memory Center.

Dr. Karlawish directs the Penn Neurodegenerative Disease Ethics and Policy Program. "This study is an important step in determining the consequences of being tested for Alzheimer's disease before the person has disabling cognitive impairments."

The A4 trial requires that patients enrolled must have one of the pathologies typically seen in Alzheimer's disease dementia, which will be assessed using a brain PET scan that measures amyloid. Given that studies have shown that about one third of clinically normal older individuals have evidence of amyloid plaque accumulation but may not develop any cognitive symptoms within their lifetime, the patients who are enrolled in the trial based on positive amyloid results may or may not go on to develop Alzheimer's disease dementia.

"In addition to the study's primary aims - looking at whether early treatment can slow cognitive decline - we will carefully measure how disclosure impacts cognitive test performance, the perception of cognitive symptoms, quality of life and perceived risk of Alzheimer's in participants with and without evidence of amyloid accumulation," said Karlawish.


'/>"/>

Contact: Kim Menard
kim.menard@uphs.upenn.edu
215-662-6183
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Indoor Memory Maker Triathlon Raises Funds for Alzheimers
2. Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency And CIDP Potentially Supplemented by Approval for Alzheimers Disease Available at ResearchMoz.us
3. Columbia study finds hospitals dont follow infection prevention rules
4. Aspirin still overprescribed for stroke prevention in AF
5. Athletes “Toward Injury Prevention in Sports” TIPS Gets Going in Las Vegas
6. Why Are Young Breast Cancer Patients More Likely to Die from Their Disease? Researchers at the Cancer Prevention Institute of California Find Answers
7. HealthyHispanicLiving Contributor Dr. Jeffrey Weitzel Discusses How Understanding the Cultural Values of Latinas Helps Raise Awareness of Breast Cancer Risk & Prevention
8. Pregnancy Stretch Marks Prevention Cream by Revitol Now Offers Extra Discount as New Year Special
9. Knellinger Dental Excellence Brings Laser Gum Disease Treatment for Bone Stimulation and Possible Tooth Loss Prevention
10. NYSATA Athletic Trainers Provide Injury Prevention and Management on Movie Set
11. “Sleepiness Prevention Tips,” A New Article On Vkool.com, Teaches People How to Fight Sleepiness Naturally - V-kool
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... ... ... In a continuous effort to raise awareness of autism and common toxins found ... natural and organic latex mattresses, has announced that they will donate $1 to the ... recent viral Facebook video receives, up to $10,000.00. , The luxury online ...
(Date:5/19/2017)... ... May 19, 2017 , ... DMG Productions is ... of Innovations with Ed Begley, Jr., airing fourth quarter 2017 on FOX Business. ... clean, organic dietary supplement made from naturally occurring ingredients. Innovations will enlighten viewers ...
(Date:5/19/2017)... ... May 19, 2017 , ... Springfield, Vermont-based law firm of Brady/Callahan has ... Good Reasons To Hire An Experienced Personal Injury Attorney, " the article offers insight ... injury. As the article says. if someone is injured due to another person's ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Miller Agency, a ... families and business owners in the region, is embarking on a cooperative charity ... their families. , Multiple sclerosis (MS) is a demyelinating disease that affects the ...
(Date:5/19/2017)... (PRWEB) , ... May 19, 2017 , ... ... containerization, today announced a sponsorship and speaking session at the 7th Annual ... the longest-running hosted enterprise mobility and digital transformation conference whose expressed purpose is ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/8/2017)... FLINT, Mich. , May 8, 2017  Diplomat ... WRB Communications, Inc. ("WRB"), a health care ... . WRB specializes in relationship management ... organizations. WRB will ... of Diplomat,s commercialization support services for manufacturers, biotech firms, ...
Breaking Medicine Technology: